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Introduction: In Germany, many Pacemakers (PM) and cardiac rhythm devices are implanted at 
specialized clinics each year. However, the impact of right ventricular leads on the tricuspid 
valve (TV) function as well as possible effects on mortality are largely unexamined. Previous 
studies show heterogeneous results. This study aims at investigating whether the presence of 
right ventricular PM leads influences TV function.  
Methods: The study was conducted retrospectively at the Charité Universitätsmedizin Berlin and 
included a total of 261 patients, of whom 123 had undergone cardiac device implantation 
between 2010 and 2016 (PM group), and 138 controls. An initial transthoracic echocardiography 
(TTE), and up to three follow-up TTEs at one month, 12 months and after a minimum of one 
year were evaluated for each patient. Primary outcome was the Grade of Tricuspid Regurgitation 
(TR). Additional secondary parameters were: TR Vmax, tricuspid annular plane systolic 
excursion (TAPSE), left ventricular ejection fraction (LVEF), systolic pulmonary artery pressure 
(SPAP), central venous pressure (CVP), vena contracta width, proximal isovelocity surface area 
(PISA) and right atrium volume (RA Vol). The cumulative survival probability for both groups 
was analyzed using the Kaplan- Meier Estimate.  
Results: The pacemaker group’s median TR Grading was significantly greater initially and long-
term than that of the control group (p=0.024 and p=<0.001). TR Grading worsened long-term 
more often in the PM group (N=34, 44%) than in the control group (N=23, 27%). The PM 
group’s overall left-heart function (LVEF) was significantly lower at all examination periods 
(p=always <0.005) and the right heart function (TAPSE) was almost always significantly worse 
(p=<0.05 for initial, mid- and long-term examination). Both parameters remained stable over 
time. The PM group’s mean RA Vol was significantly greater initially (p=0.018), however no 
great change was observed by the end of this study. Results pertaining to SPAP, vena contracta 
and PISA showed no disparities between groups. The PM group had a significantly lower 
probability of cumulative survival (p=0.016).  
Conclusion: Patients with a cardiac rhythm device had overall worse parameters pertaining to 
TV function and right and left heart function. However, most of these parameters did not majorly 
fluctuate or aggravate over time thus suggesting that the presence of an RV lead does not 







Einleitung: Jedes Jahr werden in Deutschland viele Aggregate im Rahmen des Herz-Rhythmus 
Managements in spezialisierten Kliniken implantiert. Die möglichen Auswirkungen einer 
rechtventrikulären Sonde auf die Trikuspidalklappen (TK) Funktion und auf die Mortalität ist 
jedoch noch weitestgehend unerforscht. Frühere Studie zeigten heterogene Ergebnisse. Ziel 
dieser Studie ist es, zu untersuchen, ob das Vorhandensein einer rechtsventrikulären Sonde die 
TK Funktion beeinflusst. 
Methoden: Die vorliegende Studie wurde retrospektiv an der Charité Universitätsmedizin Berlin 
durchgeführt und umfasste insgesamt 261 Patienten, von denen 123 Patienten von 2010 bis 2016 
ein Herz-Rhythmus-Gerät implantiert wurde (Schrittmacher (SM) Gruppe), sowie 138 
Kontrollen. Eine initiale transthorakale Echokardiographie (TTE) und bis zu drei nachfolgende 
TTEs innerhalb eines Monats, 12 Monaten und nach mindestens einem Jahr wurden für jeden 
Patienten ausgewertet. Der primäre Parameter war der Grad der trikuspidalen Insuffizienz (TI). 
Die zusätzlichen sekundären Parameter wurden erfasst: TI Vmax, „tricuspid annular plane 
systolic excursion“ (TAPSE: ein Wert, der für die Beurteilung der allgemeinen 
Rechtsherzfunktion herangezogen wird), linksventrikuläre Ejektionsfraktion (LVEF), 
systolischer Pulmonalarteriendruck (SPAP), zentral venöser Druck, vena contracta Weite, 
„proximal isovelocity surface area“ (PISA) und rechtes Vorhofvolumen (RA Vol). Die 
kumulative Überlebenswahrscheinlichkeit für beide Gruppen wurde mit Hilfe der Kaplan-Meier-
Schätzung analysiert.  
Ergebnisse: 
Die mediane TI-Graduierung der SM Gruppe war anfänglich und langfristig signifikant höher als 
die der Kontrollgruppe (p=0,024 und p=<0,001). Die TI-Graduierung verschlechterte sich in der 
SM Gruppe (N=34, 44%) langfristig häufiger als in der Kontrollgruppe (N=23, 27%). Die 
Gesamtfunktion des linken Herzens (LVEF) war zu allen Untersuchungszeitpunkten signifikant 
geringer (p=immer <0,005) und die Funktion des rechten Herzens (TAPSE) fast immer 
signifikant schlechter (p=<0,05 für Initial-, Mittel- und Langzeituntersuchungen) in der SM 
Gruppe. Beide Parameter blieben im Laufe der Zeit stabil. Das RA Vol der SM Gruppe war 
inital signifikant größer (p=0,018), jedoch wurde am Ende dieser Studie keine große 





Unterschiede zwischen den Gruppen. Die PM-Gruppe hatte eine signifikant geringere 
Wahrscheinlichkeit für das kumulative Überleben (p=0,016). 
Zusammenfassung: Patienten mit einem SM oder andere Aggregate hatten insgesamt schlechtere 
Parameter in Bezug auf die TV-Funktion, sowie auf die rechte und linke Herzfunktion. Die 
meisten dieser Parameter schwankten oder veränderten sich jedoch nicht wesentlich im Laufe 
der Zeit, was darauf hindeutet, dass das Vorhandensein einer rechtsventrikulären Sonde die TK 
Funktion nicht beeinflusst. Allerdings impliziert diese Studie, dass Patienten mit einem SM eine 


















1. 1. The First Pacemakers 
The earliest attempts at devising pacemakers (PM) took place in the 1930s when Albert Hyman 
created the so-called Hyman Oter3,4. Roughly two decades later, the first devices similar to those 
today were developed concurrently in the USA and Europe, mainly in Sweden5. In 1952 the 
cardiologist Paul Zoll designed an external PM4 and in 1956, the American Engineer Wilson 
Greatbatch and Andrew Gage developed the first PM with mercury zinc batteries4. In 1957 
Vincent Gott, John Johnson and Clarence W. Lillehei came together and constructed a temporary 
cardiac pacer3,5. It was also Lillehei who instructed the engineer Earl Bakken to create a 
permanent construction3. The engineer Rune Elmqvist in Sweden designed a PM that same 
year5. Even though there are many individuals associated with the development of PMs 
coincidently, it is necessary to name all of them as each person contributed separately to a 
specific mechanical feature. There were many differences concerning the battery composition, 
battery life, polarity and general design3,6.  
Despite the technical differences across the globe, the first permanent implantations of a PM in 
humans occurred parallel and under similar circumstances. In 1958 in Stockholm Elmqvist 
together with the Swedish Surgeon Åke Senning implanted the first PM into a human, who had 
suffered from complete heart block and consequently Adam-Stokes attacks3,5. This patient 
continued to live for 43 years and died of an unrelated cause4. Briefly thereafter in 1960, William 
Chadack implanted the first PM designed by Greatbatch in Buffalo New York. The patient was 
77 years old and also suffered from symptomatic complete AV Block3. The outcome of this 
specific patient is unknown, however the following implantations demonstrated that 
Greatbatch’s PM had a lifespan of one to five years3.  
After a whirlwind of PM engineering and experimenting within the one decade, the ones 
afterwards concentrated on solving the problems concerning battery life and materials used in 
the devices. Chadack and Elmqvuist are only exemplary and the most renown amongst the many 
people involved and attempts that took place over time during the evolution of PMs. John 
Schwedel, Seymour Furman, William Glenn and Alexander Mauro in the USA, Robert Rubio in 
Uruguay, Lagergran in Sweden and Mohammed Khalilullah in India are few examples of 





1. 2. The Modern Pacemaker 
1. 2. 1. Cardiac Electrical Conduction System 
In order to understand how a PM or a similar device works, one must understand how the heart’s 
own natural electrical conducting system works and what types of illnesses they can be used for.  
  Image 1: the anatomical electrical conducting system of the heart, here marked in green. The image is from 
 the Stanford Children’s’ Hospital website2. 
Generally speaking, the conduction system of the heart allows signals to spread across the heart 
enabling it to contract as a muscle in an organized manner7. Physiologically the initial action 
potential starts in the sinoatrial node, which is located in the upper right posterior part of the 
right atrium (RA),. The sinoatrial node creates action potential autonomously with an underlying 
heart frequency of around 60 to 100 beats per minute. From here on, the action potential spreads 
across the RA via three internodal tracts and is thought to spread to the left atrium (LA) via the 
Bachmann’s Bundle. It then arrives at the Atrioventricular node, located at the interatrial septum. 
Only after a certain delay does the action potential spread to the His Bundle and to its right and 
left bundle branches. Labeled in Image 1 as “Conduction Pathways” are the Purkinje Fibers, 
leading the action potential into the myocardial muscle tissue7,8. 
 





 1. 2. 2. Cardiac Arrhythmias and Desynchronized Heart Function 
The type of arrhythmia depends on where the problem or disruption within the electrical 
conducting system or myocardia is located. Principally arrhythmias can be divided in to 
bradycardia with a heart rate below 60 beats per minute and tachycardia, with a heart rate above 
100 beats per minute. Additionally, most arrhythmias can be idiopathic or caused by pre-existing 
cardiac damage leading to fibrosis or myocarditis, such as an occurred myocardial infarction, 
infection, congenital circumstances, cardiomyopathy, arterial hypertension or coronary artery 
disease7-10.  
Sick Sinus Syndrome (SSS) summarizes a group of illnesses that cause dysfunction in the sinus 
node and encompasses many symptoms, including both brady- as well as tachycardia.  It can 
appear as sinus bradycardia, which is when the sinus node itself doesn’t create enough action 
potential and thus heart contractions per minute. Sinus pauses of over 3 seconds can occur as 
well. Lastly, bradycardia-tachycardia syndrome is a condition in which both heart rate 
pathologies occur alternately7,8.  
Atrioventricular Conduction Block (AV-Block) is an illness, in which the transmission of action 
potential from the atria to the His Bundle is delayed or entirely prevented due to damage in 
either location. First degree AV-Block is when the PQ-interval is always over 200ms but doesn’t 
alter in length at any given time. Most of these patients are not symptomatic. Second degree AV-
Block is divided into Mobitz Type I and Type II. Type I is when the PQ-interval repeatedly 
gradually gets longer until there is no contraction after a p-wave. Type II is when a contraction 
repeatedly does not occur after p-wave, but the PR-interval remains constant. At this point 
patients can become symptomatic. Third degree AV-Block is almost always symptomatic, as 
there is no conduction between the atria and His Bundle at all anymore. In this case, the His 
Bundle can create an autonomous frequency of about 40 beats per minute on its own. However, a 
third degree AV-Block can cause such a haemodynamic disruption, that a patient can suffer a 
syncope, then also called Adam Stokes Attack. All AV-Blocks are categorized as 
bradycardia7,8,11. Furthermore, AV-Blocks can principally be described as having an intrinsic or 
extrinsic cause. Intrinsic means, the AV-Block is due to a problem within the heart itself, such 
mechanisms are mostly connected to Adam Stokes Attacks. Extrinsic means the cause is 
elsewhere: either due to parasympathetical vagal nerve dysregulation, linked to the development 





one of the mechanisms involved in low-adenosine syncope“12, or can be a manifestion of a 
complication of other diseases such as Lyme carditis13. 
Tachycardia can be attributed to problems in the atria or ventricles. Atrial Fibrillation (AF) is 
one of the most common arrhythmias. In Germany alone it is diagnosed in 10% of patients over 
the age of 80 years14 and worldwide “the current estimate of the prevalence of AF in the 
developed world is approximately 1.5-2% of the general population”15. AF is when undirected 
excitation occurs across the atria causing uncoordinated contractions of the atria. This leads to 
the irregular conduction of impulses to the ventricles, causing a heart rate of up to 300-600 beats 
per minute, also called tachycardia absoluta. In some cases, impulses are conducted so 
unregularly and unreliably, that it induces a paradox bradycardia absoluta7,8.  
A re-entry mechanism is an electrical impulse that gets conducted over and over again at a 
specific location in the myocardia or conduction system. This can happen when a short circuit 
develops because a branch in the conduction system is blocked or damaged. Re-Entry can cause 
tachycardia in the atria as well as in ventricles and can be paroxysmal7,8,16.  
Ventricular tachycardia (VT) is a general term used to describe when tachycardia is due to 
problems in the ventricles. Apart from re-entry mechanisms, there are two other special forms of 
tachycardia worth mentioning: ventricular fibrillation (VF) and torsade de pointes. VF is when 
there is an undirected and completely unorganized contraction of the ventricles up to 400 beats 
per minute causing death. Torsade de pointe is seen as state of transition into VF but can also 
sustain spontaneously and is characterized by a specific pattern in an electrocardiogram (ECG) 
known as its translation “twisting of the peaks”. 7,8,17. 
Not only cardiac arrhythmias induce uncoordinated cardiac contraction. For example, the right or 
left bundle branch conduction can be compromised. A blockage leads to the muscle tissue it 
activates not contracting anymore. If a patient suffers from an underlying heart disease or if more 
than one branch is affected, the heart’s contraction can be severely impaired, even inducing heart 
failure (HF). However, the right bundle block is more likely to be less symptomatic, as the right 
ventricle (RV) can still be activated by the left branch. Additionally, the left bundle branch block 
occurs more often due to degenerative diseases or damage caused by prior myocardia infarcts, 





1. 2. 3. Heart Rhythm Devices and their Indications 
There are several types of devices used for cardiac pacing. Which device is implanted depends 
on the indication or rather which underlying heart rhythm disturbances or dysfunctions have 
been diagnosed.  
1. 2. 3. 1. Pacemaker 
First and foremost there is the PM, which basically is an electrical device that sends electrical 
impulses to the heart either causing it to contract faster or slower. As shown below (Image 2), 
the small generator is usually placed subcutaneously under the collarbone. There are leads 
attached to it, which connect the electrodes at the end of them to the generator. They are inserted 
via the subclavian vein and are pushed forward through the superior vena cave and enter the 
heart via the RA and pushed further through the tricuspid valve (TV) into the RV if necessary. 
The electrodes are then positioned into the heart wall of the chamber they are in19-22.  
Image 2: Dual Chamber Pacemaker19 
 
The electrodes register the heart’s electrical activity and pass on this information to the 
generator, where it is computed and the according electrical response is sent back via the leads to 
Image  2: An implanted dual chamber pacemaker. Two separate electrodes and leads are 






the electrodes. Depending on the settings of the PM, a device can either register bradycardia, 
tachycardia or a normal heart beat and in response either stimulate or suppress depolarization 
within the heart muscle tissue23. 
General surgical complications after a PM implantation include “wound infection, bleeding, 
thrombosis, pulmonary artery embolism, nerve damage or tissue damage due to poor positioning 
during the intervention”24. Furthermore, specific complications include possible damage from 
puncturing such as pneumothorax, hemothorax, heart perforation with pericardial effusion and 
tamponade, air embolism, or other accidental perforation of blood vessels.25 The leads 
themselves can also lead to complications, such as irritation in the myocardium paradoxically 
inducing arrhythmia, or can dislocate after the procedure possibly damaging surrounding 
tissue24. However, the overall risk of a PM implantation is low nowadays and can be performed 
rather securely24. 
There is the universal NBG code used for describing PMs technically consisting of up to five 
letters. It was created together by the North American Society of Pacing and Electrophysiology 
(NASPE) and British Pacing and Electrophysiology Group (BPEG)26,27. The table below cited 
from Bernstein et. al.27 summarizes what each of the five letter positions symbolize. 
Table 1: NBG Pacemaker Code27 











Letter and Meaning  0 = None 
A = Atrium 
V = Ventricle 
D = Dual (A+V) 
 
S= Single (A or 
V) 
0 = None 
A = Atrium 
V = Ventricle 
D = Dual (A+V) 
 
S= Single (A or 
V) 
0 = None 
T = Triggerred 
I = Inhibited 
D = dual (T+I) 
0 = None 
R = Rate 
Modulation 
0 = None 
A = Atrium 
V = Ventricle 
D = Dual 
(A+V) 
 
Table 1 lists and explains the different possibilities for the five letter NBG code used to define PM design and 
settings.  
The first position describes in which chamber the electrodes register the heart’s activity and the 
second position describes in which chamber the electrodes send signals to. The third position 
describes how or when the PM sends signals. Triggered means the device will only stimulate if 
intrinsic activity is sensed. If, for instance, there is impaired conduction in the AV-Node, the 





heart rate. Inhibited means that the device only sends impulses if no intrinsic activity is sensed. 
For example, if the Sinus node does not stimulate enough on its own, the PM can do so until it 
does, but no atrial to ventricular coordination is given. The fourth positions describes as to 
whether the device can adapt the stimulated heart rate according to the patients bodily functions 
such as exercise or sleep. The fifth position describes if the device stimulates in more than one 
area within a chamber, however this letter is used less than the others26,27. 
1. 2. 3. 2. Implanted Cardioverter Defibrillator 
An implantable cardioverter defibrillator (ICD) detects ECG irregularities such as VT and in 
response is able to defibrillate the heart with its electrodes. An ICD is usually combined with a 
PM, but does not have to be28. An ICD must have a minimum of one electrode in the RV in order 
to correctly sense an arrhythmia and apply an electrical shock, using the generator as an antipole 
to the electrode29. 
1. 2. 3. 3 Cardiac Resynchronization Therapy 
A cardiac resynchronization therapy (CRT) device allows atrium-synchronized biventricular 
pacing. A CRT typically has one sensing electrode in the RA and two pacing electrodes, one 
right ventricular and the other left ventricular externally along the coronary sinus30. It paces 
according to atrial impulse generation and secures a more simultaneous, coordinated contraction 
of the ventricles, hereby improving the heart’s overall pump function29,31. 
1. 2. 4. Indications for Cardiac Pacing  
1. 2. 4. 1. Indications for Pacemaker 
One group of patients for whom a PM is relevant for are patients with bradycardia. Symptomatic 
persistent SSS and symptomatic intermittent SSS are both indications for a PM implantation, 
mostly two chambered32,33. An intrinsic persistent or intermittent AV-Block second or third 
degree, regardless of whether they are symptomatic or not, are also indications for a PM, mostly 
two chambered as well32-34. A bundle branch block with a positive electrical physiological 
examination or an alternating bundle branch block, regardless of whether it is symptomatic or 
not, are further indications for a PM implantation32,33. The presence of an AV-Block and 
persistent VF are also indications for a PM, however rather one chambered in the RV32. Patients 





to the carotid arteries, causes a symptomatic decline in heart rate, including everyday activities 
such as turning one’s head35.  
There are some constellations in which the implantation of a PM is not primarily indicated but 
should be considered based upon other factors such as older age, risk of falling with injuries or 
accompanying illnesses, especially cardiac. These include AV-Block second degree Type I 
located either infra- or intra-hisian, asymptomatic Sinus pauses or syncopes without diagnostic 
findings32,33. In these cases, the implantation of a PM has to be carefully considered by a 
physician based upon the individual situation of the patient. If a patient develops a relevant and 
persistent arrhythmia such as AV-Block after a myocardial infarction or cardiac surgery, then a 
PM can be necessary32,33. 
All reversible bradycardia, due to intoxications for instance, are not an indication for a PM 
implantation32,33. A documented but not symptomatic bradycardia is not an indication as well32. 
A physiological bradycardia, such as in athletes, is not an indication for a PM either32. Lastly, an 
asymptomatic single bundle block is also not primarily an indication32.  
In Germany in the year 2015, SSS was the most common indication making up 36,6% of all 
indications for newly implanted devices36. Second was third degree AV-Block with 29,3 %, 
however when including first and second degree diagnoses, AV-Block over-all was the most 
common reason for a new PM making up almost half of the indications, namely 43,3%36. Three 
fourths of devices were set in D-D-D, followed be V-V-I and only a minute portion of patients 
received a CRT36. Amongst all newly implanted PMs, 42,4% of the patients were over 8.0 years 
old36 
1. 2. 4. 2. Indications for an Implantable Cardioverter Defibrillator  
An ICD can be implanted for primary or secondary prophylactic reasons. Concerning primary 
prophylaxis, indications for an ICD implantation encompass mostly hereditary diseases 
regarding arrhythmias and myopathies such as Brugada Syndrome, Long-QT syndrome and 
genetic disorders with an increased risk of sudden cardiac death such as hypertrophic 
cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy37.  
An ICD can be considered for primary prophylaxis for patients who have a secondary high risk 
of arrhythmia, for example for patients with cardiomyopathy, whose LVEF remains lower than 





The indication for a secondary prophylactic ICD is essentially based upon the presence or 
occurrence of hemodynamic unstable ventricular tachycardic conditions.  An ICD is primarily 
indicated when VF or generally VT induce cardiac arrest, syncopes or cardiac shock or no 
specific cause is found for such conditions37. If a syncope was not documented in an ECG, but a 
patient’s LVEF is ≤ 40 % and VT is inducible, then an ICD is indicated as well37. Another 
indication for a single chamber ICD is HF with a NYHA classification of II-III where LVEF is ≤ 
45%37. Furthermore, patients who have suffered myocardial infarction longer than four weeks 
ago and have a LVEF of ≤ 30% also qualify for an ICD37.  
1. 2. 4. 3. Indication for Cardiac Resynchronization Therapy 
The indication for a CRT largely depends on the QRS complex in the ECG, left ventricular 
ejection fraction (LVEF) and accompanying arrhythmias. If a left bundle block is present, LVEF 
is less than 35%, New York Heart Association (NYHA) classification is II, III, IV and the QRS 
complex is greater than 120ms, the implantation of a CRT is indicated, almost always 
biventricular32,33. Over all, clinical practice shows that female patients with a broadened QRS 
complex, left bundle block and non-ischemic cardiomyopathy respond best to CRT32. In 
Germany in 2011, roughly 5-10% of patients with HF had a clinical indication for a CRT32. 
A CRT implantation should or can be considered but is not primarily indicated if the bundle 
block is not left, the LVEF is less than 35%, the NHYA classification is II-IV and the QRS 
complex is greater than 120ms32,33. The same situation applies to patients with persistent VF, low 
LVEF and a broadened QRS complex32.  
An isolated LVEF below 35% with a QRS complex less than 120ms is not an indication for a 
CRT32.  
If an ICD therapy is planned, then a CRT-D device should be implanted32,33. However, if a 
patient has a life expectancy of under one year due to severely advanced HF, severe kidney 
failure or dialysis, cachexia, fragility or other severe accompanying illness a CRT-P should be 
considered instead due to less expected complications after its implantation32,33.  
1. 3. The Tricuspid Valve  
1. 3. 1. Anatomy and Function of the Tricuspid Valve 






The TV is located between the RA and RV, thus its latin name “valva atrioventricularis dextra”38 
(Image 3). There are three leaflets, namely cuspis anterior, posterior and septalis, consisting of a 
thin avascular connective tissue, covered with endocardium38. The leaflets are joined onto a ring-
like base, or annulus, and strung by the chordae tendinae onto the papillary muscles which 
connect the leaflets to the RV wall, enabling the valve to close38. The TV’s role is to  prevent 
blood streaming back from the RV into the RA during a systole, while the RV contracts and the 
pressure in the RV exceeds the pressure in the RA38. 
1. 3. 2. Pathophysiology of the Tricuspid Valve 
Valvular heart diseases (VHDs) are the most common cardiovascular diseases following arterial 
hypertension and coronary heart disease39-41. Principally VHDs are etiologically divided into 
congenital and acquired diseases, the latter encompassing degenerative processes, infections or 
rheumatic events. Furthermore, VHDs are classified as valvular stenoses, a narrowing of the 
valve’s diameter, or valvular insufficiencies, also known as regurgitation. This means that the 
valve does not close completely and blood can flow retrograde42,43. The most common VHD in 
Image  3: Anatomy of the Tricuspid Valve1 
Image 3: Anatomy of the right and left heart, showing the exact location of the TV, the chordae 
tendinae and papillary muscles. The image is from Mazur et al.’s book “CT Atlas of Adult Congenital 
Heart Disease”36. Ao: aorta, IVC: inferior vena cava, MPA: main pulmonary artery, PM: papillary 
muscle, PV: pulmonary valve, RA: right atrium, RAA: right atrial appendage, SMT: septomarginal 






Germany is aortic valve stenosis, which accounts for 43% of all VHDs42, followed by mitral 
valve insufficiency with 10-15%43, of which the majority of both are acquired diseases43.  
Diseases of the TV occur less making up approximately 4-5% of the acquired valve defects44. 
Tricuspid Regurgitation (TR) however is more common than tricuspid stenosis, which is almost 
exclusively a complication of rheumatic fever45. TR is often accompanied by other VHD of the 
left heart46. 
Acquired TR is much more frequent than congenital TR. Acquired TR can be caused by direct 
lesions to the TV, a so-called “organic” origin, including bacterial infections, carcinoid 
syndrome, trauma or rheumatic fever45. Much more common however, is TR caused by a 
secondary dilation of the annulus, a so-called “functional” origin45.  In most cases, it is caused by 
pre-existing diseases of the left heart or pulmonary circulation, which increase the overall 
pressure in the right heart. Examples are pulmonary arterial hypertension (PAH), pulmonary or 
pulmonary valve stenosis, RV myocardial infarction, RV cardiomyopathy or left heart failure 
(LHF)18,45,47-49. 
In TR, blood flows from the right ventricle back into the right atrium during systole, due to the 
lack of sealing by the pathologically altered TV. Incipiently, this can remain without major 
hemodynamic effects, or rather can be tolerated for a period of time depending on the general 
condition of the heart47. The aftermath of the backflow of blood into the RA depends on the 
duration and the actual volume of the blood flowing back. Over time, a greater diastolic pressure 
is needed in the RA to push the additional blood back from the RV at atrial level, which can lead 
to RA hypertrophy. If, regardless of the etiology, the mean pressure in the pulmonary circulation 
is increased, the afterload of the RV increases and there must be an increase in pressure in the 
systole as well in order to eject the blood. This in can additionally lead to right ventricular 
hypertrophy. In the long run, this can lead to cardiac insufficiency. In the worst case, because the 
effective cardiac output is decreased, this can induce acute right heart decompensation in the 
event of sudden pressure increases, such as pulmonary artery embolism, or increased physical 
activity44,46,47. 
Harrison’s Principle of Medicine states that “the tricuspid valve is the most underestimated 






1. 4. How to diagnose Tricuspid Regurgitation 
1. 4. 1. Clinical Symptoms 
The clinical symptoms of TR are mostly contingent on the presence and extent of accompanying 
right heart failure (RHF) or even LHF, as TR is often not the singularly diagnosed VHD. The 
symptoms of RHF include fatigue, exertional dyspnoea according to the NYHA criteria50, weight 
gain and peripheral oedemas, feeling of fullness or bloatedness, lack of appetite and a distended 
abdomen, a visible jugular vein congestion hepatomegaly with systolic pulsations, ascites, and 
reflux. TR is symptomatic in auscultation as a holosystolic, highfrequent sound in the fourth or 
fifth intercostal space left parasternal or in the xiphoid region. This sound is intensified during 
inspiration, which is called the “Carvallo’s Sign”46. A third heart tone can appear as well. This 
breathing dependency is pivotal, as the auscultation symptoms can otherwise easily be confused 
with mitral regurgitation18,46,51.  
1. 4. 2. Tricuspid Regurgitation Classification and Echocardiology 
TR can also be diagnosed with medical imaging techniques. A chest x-ray might reveal indirect 
signs such as an enlarged heart. Nevertheless, echocardiography is the standard procedure of 
documenting TR. Table 2 summarizes qualitative, semi-quantitative and quantitative methods of 
recording TR51. 
Table 2:  Echocardiographic Values for Observing Tricuspid Regurgitation52-54 
 Methods Mild TR Moderate TR Severe TR 
Qualitive 
Intensity of Insufficiency Jet 
in RA dense/triangular, early peaking         + 
Valve Morphology abnormal/flailing leaflets                 + 
Volume of Systolic 
Insufficiency Jet into RA < 1/3 1/3- 2/3 > 2/3 
Semi-
Quantitative 
Vena Contracta Width (mm) < 6 ≥ 7 ≥ 7 
PISA Radius (cm) < 9 < 9 ≥ 9 
Systolic Reverse Hepatic 
Vein Flow / ++ +++ 
Quantitative 
EROA (cm2) < 40 < 40 ≥ 40 
R Vol (ml/beat) < 45 < 45 ≥ 45 
RA and RV Enlargement - -/+ ++ 
Other 
CVP mmHg / + ++ 





TR Vmax (m/s2) ≥ 2.8 is considered pathological 
Table 2: Overview of echocardiographic values used for describing TR53,54. PISA: Proximal Isovelocity hemispheric 
Surface Area; EROA: Effective Regurgitant Orrifice Area; R Vol: Regurgitant Volume, TAPSE: Tricuspid Annular 
Plane Systolic Excursion; CVP: Central Venous Pressure; TR Vmax: TR maximum Jet Velocity; mmHG: 
millimeters of mercury. 
 
One approach to assess TR is the optical observation of the systolic insufficiency jet itself which 
is the blood that streams into the RA in the case of TR. The denser the signal and the more area it 
seems to take up in the RA in a colored-doppler sonography, the worse TR can be expected. 
Early peaking refers to the resulting parabel shape of the velocity curve, in which the velocity 
decreases in the late systolic period quicker than usual. Additionally, one can examine the TV 
itself and try to identify a morphological abnormality. Vena contracta refers to the smallest 
diameter at the narrowest part of the insufficiency jet underneath the opening of the respective 
valve. The wider it is, the worse TR can be estimated. The PISA radius is used to estimate the 
surface area of the valve opening, through which the blood of the regurgitation jet flows. This is 
also known as EROA. An increase in both implies that more blood flows retrograde through the 
TV.  Furthermore, reverse hepatic vein flow, which does not occur physiologically, is a sign of 
reduced right heart function.  RA and RV enlargement and an increased CVP are possible 
consequences of TR. The greater the dilation and CVP, the more likely TR is severe. TAPSE is 
also a value that is used to asses overall right heart function, which can be reduced if TR is 
severe. Lastly, TR Vmax is used to estimate the right heart’s maximum pressure, which is 
increased in advanced TR. It can also be used to estimate whether a patient has PAH, which is 
sometimes diagnosed parallel to TR and can worsen it54-58. 
It is important to note that all of these values must be interpreted collectively. The 
echocardiographic values can be pathological independently from one another, without making 
the occurrence of another value obligate. They must also be considered in contextually to the 
clinical symptoms reported by a patient. Lastly, the more advanced the TR is, the easier it is to 
measure these values. If the TR is incipient, some of these values can lie within normal range or 
be ambiguous18,56,59.  
1. 5. Aim of the study 
Germany has one of the highest new implantation and exchange rates of PMs in Europe. In 2011, 
about 1291 PM implantations and exchanges per million population occurred in Germany, which 





of new implantations has since decreased minimally,  however the number of PM unit exchanges 
has risen36. Yet all together, the number of PM operations remains high in comparison. In 2015 
in Germany for example, it totaled to 75,730 operations36. That same year, Germany still had the 
highest number of new implantations per million population with 922 operations compared to 
Denmark, Switzerland and Sweden36.  
Commonly described complications after PM implantations pertain primarily to surgical 
aftermath. There are some complications though that have not been scientifically secured. In the 
case of a PM including a RV lead, the lead not only passes through, but remains lying in the 
tricuspid valve after implantation. Some authors suspect that this could lead to TR as a long-term 
complication after implantation46,60-63. As specified above, TR alone can induce severe medical 
consequences. If this phenomenon after PM implantation is veracious, it can have a far-reaching 
effect, especially considering the high number of interventions.  
Findings in literature regarding this suspicion are nevertheless heterogenous and inconstant. The 
aim of this study is to examine the possible correlation between PM implantation and TR in 
accordance with reliable scientific standard and quality.  
1. 5. 1. Research Questions 
The aim of this study is to investigate the following research questions: 
• Does the implantation of a cardiac rhythm device influence the TV function, and can it 
induce TR? 
• Which parameters regarding the TV does the implantation of a cardiac device affect? 








2. 1. General Study Design 
The study was conducted retrospectively at the Charité Universitätsmedizin Berlin, Germany in 
2016 until 2018. The study compared data between a PM group and a control group. Two-
dimensional transthoracic echocardiographic follow-ups at different time intervals, focused on 
the evaluation of the tricuspid valve function, as well as baseline characteristics were examined 
for both groups. Furthermore, it was recorded whether patients in both groups were still alive or 
deceased.  
2. 2. Ethics Votum 
The Study was approved by the Ethics Committee of the Charité Universitätsmedizin Berlin, 
Germany (Order Number: EA1/394/16). 
2.3. Study Population 
2. 3. 1. PM Group 
First, a pool of patients eligible for the study for the PM group were recruited. This consisted of 
all patients who had received one of the following four implantable cardiac rhythm devices at the 
Charité Universitätsmedizin Berlin between 2010 to including 2016: PM (PM), implantable 
cardioverter defibrillator (ICD), cardiac resynchronization therapy (CRT) or cardiac contractility 
modulation (CCM).  .  
The patients had to have had at least one echocardiography performed at the Charité Berlin, 
Campus Benjamin Franklin during the same time period. Both men and women from the age of 
18 years onwards were included. The patients’ initial indications for the implantation of the 
devices were not regarded. The number of devices implanted per patient and the individual 
frequency settings of the devices were also not regarded. 
In a second step, patients were removed from the original pool if the following criteria did not 
apply: 
• Each patient had to have at least one two-dimensional transthoracic echocardiography 





• The TTEs before and after the implantation had to include an examination of the 
tricuspid valve. 
• Each TTE had to be fully documented, including the images that were made during the 
examination. 
• The implanted devices were not limited in lead number as long as at least one lead passed 
through the tricuspid valve. 
• A patient did not undergo catheter ablation 
In a final step, the remaining patients were divided into groups depending on when their follow-
up TTE examinations had been performed. Patients was assigned to one of the three groups: 
follow-up within 30 days after implantation, follow-up within 12 months after the implantation 
and follow-up at least one year after the implantation.  
2. 3. 2. Control Group 
Based on the characteristics of the final PM group, a pool of patients eligible for the study for the 
control group were recruited. This consisted of all patients, who had received at least two 
echocardiographies at the Charité Universitätsmedizin Berlin, Campus Benjamin Franklin 
between 2010 to including 2016. Both men and women from 29 to 93 years of age were 
included. The patients were not allowed to have any cardiac device implanted or have undergone 
catheter ablation within their entire lifespan.  
In this original pool of patients, it was not technically possible to have the gender of the patients 
automatically listed. The gender male or female was assigned manually to each individual 
patient. All patients whose gender could not be clearly assigned were removed from the original 
pool.  
In a third step, all patients who received less than four echocardiographic examinations were 
removed from the original pool. Here could not yet be differentiated whether the examination 
was a TTE or a transesophageal echocardiography (TEE). 
The remaining patients in the control group were then matched with the patients in the PM group 
based on their gender and age. If an exact match in age was not possible, an age difference of +/- 





The remaining matches were then re-evaluated. The final patients for the control group were 
chosen manually based upon mutual baseline characteristics to the PM group. Final patients for 
the control group were chosen if the following criteria applied: 
• The control had the same Body Mass Index (BMI) classification as the exposed 
and 
• The control had the same amount of diagnosed accompanying illnesses 
Controls who had the same or similar diagnosed accompanying illnesses were preferred. If a 
control had the identical diagnosed accompanying illnesses, but did not have the same BMI 
classification, the patient was included in the control group if the BMI did not differ from the 
PM’s by more than 5kg/m2.  
If no control could be matched to a patient in the PM group, this patient was excluded from the 
PM group. 
Finally, the patients in the control group were assigned to the same follow-up groups concerning 
their echocardiographic examinations as the PM group.  
2. 4. Baseline Characteristics  
The following baseline characteristics were recorded for both the PM and the control group:  
• whether any other cardiovascular operation had been performed, such as a bypass or 
valve replacement 
• whether the patients had been diagnosed with coronary heart disease, renal insufficiency, 
peripheral artery disease, arterial hypertension, diabetes Type I or II, pulmonary 
embolism or stroke  
• BMI in kg/m2 
The BMI was classified into the four following groups based on the recommendations of the 






Table 3: BMI Classification according to the WHO63  
BMI in kg/m2 Classification Assigned Numeral 
<18,5 underweight I 
18,5-24,9 normal weight II 
≥25,0 overweight III 
≥30,0 obese IV 
        Table 3 lists the BMI classifications used in clinical practice.  
For every patient in the PM group, the type of cardiac device as well as how many chambers and 
leads they had were recorded. 
2. 5. TTE Evaluation 
The procedure of evaluating the TTEs was the same for both the patients in the PM, as well as 
the control group. The TTEs were two-dimensional, performed by experienced examiners in the 
Charité Universitätsmedizin Berlin between 2010 until 2016 using a Vivid E9 Ultrasound 
System, manufactured by GE Healthcare. 
Each Patient had an initial TTE. In the PM group, this was the TTE before a cardiac rhythm 
device was implanted. In the control group, it was the patient’s chronologically first TTE. For 
each patient a total of maximum three TTE follow-ups were evaluated, depending on whether a 
TTE had been performed within one month, within 12 months or after a minimum of one year 
after the initial examination. If a patient had more than one TTE within one time-frame, the 
chronologically latest examination was included. The patients did not have to have a TTE for 
each time-frame.  
For each TTE evaluation, echocardiographic images and written reports were included. The 
diagnosed Tricuspid Regurgitation (TR) Grading and other measurements were recorded from 
written reports. The maximum tricuspid regurgitation velocity in m/sec (TR Vmax), vena 
contracta width in mm, RA volume and the PISA in ml were derived manually from the 
echocardiographic images.  
2. 5. 1. Written Reports 
For each examination, the exact TR Grading diagnosed by the examiner was recorded, whether it 
was documented as a roman numeral or written out. Examiners recorded the TR Grade singular 





classifications, namely 0, I, II and III with III being most severe. This study classified the TR in 
half steps allowing seven possible classifications, shown in Table 4. 
Table 4: TR Classification used in this Study 
TR Grade Roman Numeral  
(diagnosed by Examiner) 
TR Grade written out  
(diagnosed by examiner) 
Recorded TR Classification 
0 none 0 
0-I trace 0,5 
I mild 1,0 
I-II mild to moderate 1,5 
II moderate 2,0 
II-III moderate to severe 2,5 
III severe 3,0 
Table 4 describes how the TR gradings in written reports evaluated in this study were documented. The 
documentation allowed TR to be categorized precisely into half steps. 
Additionally, the following results were recorded from the written reports: 
• tricuspid annular plane systolic excursion (TAPSE) in mm 
• left ventricular ejection fraction (LVEF) in % 
• pulmonary arterial pressure (PAP) in mmHg 
• central venous pressure (CVP) in mmHg 
If no CVP had been documented, a CVP of 5mmHg was assumed56,65.  
2. 5. 2. TTE Images 
The TR Vmax was measured manually using the images made during an echocardiography by 











Image  4 Measurement of the TR Vmax (original image from study) 
 
Image 4: original echocardiographic image made in this study demonstrating how the TR Vmax was determined.  
The images used for measurements were accessed retrospectively. They were apical four 
chamber views with a continuous wave doppler focused on the tricuspid valve. As shown in 
Image X, the tricuspid valve’s regurgitation velocity was then displayed. In this study, the 
velocity in m/s was measured manually using a measuring tool available in Centricity 
CARDDAS Xi2 Program. A line was drawn from the zero line (x axis) to the maximum point on 
the curve (y axis).  
Furthermore, the following three values were derived manually from echocardiographic images 
as well: 
• The width of the vena contracta in mm  
• PISA in mm 






2. 5. 3. Calculated Data 
The systolic pulmonary Artery Pressure (SPAP) was calculated additionally to the recorded PAP 
based on the modified Bernoulli Equation66:  
PPA-Syst = 4 x (TR Vmax)2 + CVP 
where: 
PPA-Syst: systolic pulmonary Artery Pressure in mmHg 
TR Vmax: maximum tricuspid regurgitation velocity in m/sec; here used as the pressure gradient 
between the RV and RA67 
CVP: central venous pressure in mmHg 
2. 6. 1. Enquiry 
On the 24th of April 2018, an enquiry was made at the Landesamt für Bürger- und 
Ordnungsangelegenheiten Berlin, Germany (State Office for Residents’ and Regulatory Affairs). 
This enquiry was a request on information as to whether all patients in this study were registered 
as alive or deceased. A request only applied if patients were registered in Berlin, Germany. For 
each request, the name and date of birth for each person was stated. The enquiry was made via 
iDGARD System, an official electronic document management system that allowed a secure and 
protected upload, provided by the Landesamt für Bürger- und Ordnungsangelegenheiten Berlin, 
Germany.  
2. 6. 1. Granted Enquiry 
The enquiry was granted on the 25th of April 2018. Information as to whether a patient was 
registered as alive or deceased was provided for each patient. If a patient was deceased, the date 
of death was stated. No information could be provided if one of the following three situations 
occurred: a patient was not registered in Berlin, Germany; there was more than one person with 
the same name and date of birth; there was a ban on disclosure for a patient, due to legal reasons 
for example. It was not specifically named, which situation applied if no information was 





2. 7. Data Acquisition and Presentation 
Data was recorded retrospectively and obtained through medical reports and patient records in 
the Charité SAP Software System. Additional echocardiographic information was obtained 
through the Centricity CARDDAS Xi2 Program. The collected data was documented in tables in 
Microsoft Excel Version 15.27 and SPSS Version 24.0 (German Language). All graphics and 
charts were created using both of these programs.  
When data gathering was completed, the patients included were anonymized and checked for 
duplicates.  
2. 8. Statistics 
All statistical tests were performed using SPSS Version 24.0 and Stata Software 15. The 
statistical procedures were consulted by and conducted with the help of the Institute of medical 
Biometrics und clinical Epidemiology of the Charité Berlin. All graphs were created with SPSS 
Version 24.0 and Microsoft Excel Version 15.41.  
2. 8. 1. Descriptive Statistics 
All variables were tested for normal distribution graphically by evaluating each individual 
variable’s histogram, specifically by assessing their skewness. For all nominal variables, 
absolute and relative frequencies were shown.  Ordinal scaled variables were characterized by 
their median and interquartile range (IQR). Interval scaled variables were characterized by their 
mean and standard deviation (SD).  
2. 8. 2. Statistical Tests 
The baseline characteristics were analyzed and the p-values were calculated from either a linear 
mixed model (random intercept model) or a binary mixed model (random intercept model) using 
SPSS 24.0 or STATA 15.  
For the following tests (Wilcoxon Signed-Rank, mixed linear model; described below), the 
control group’s results were only included, if the matched patient in the PM group had 
corresponding data for the equivalent follow-up.  
The median values for TR, mean TR Vmax, TAPSE and LVEF for all follow-up periods for both 





following assumptions were met: the independent variable was paired and the dependent variable 
was at least ordinal scaled, it was only approximately normally distributed but it had an 
approximately symmetrical distribution of differences68,69. A significance level was set at 
p<0.05. Each follow-up period was compared to the initial TTE separately.  
The observed echocardiographic data was analyzed using a mixed linear model for paired 
variables on SPSS Version 24.0. This test was used to compare the observations explicitly 
between the PM and control group. It was assumed that all variables were normally or 
approximately normally distributed. Time was not set as continuous. A significance level of 
p<0.05 was chosen. The three levels applied were: the match identification (a paired PM and 
control patient shared one match identification), the patient’s individual identification (every 
patient included in this study received their own individual identification) and the recorded 
variable being compared. The medians and means of each characteristic for each follow-up 
period were compared between the PM and the control group in order to assume whether 
differences were statistically significant.   
The Kaplan-Meier survival curve was created using SPSS Version 24.0. The beginning date of 
the observation period was the first echocardiographic examination performed amongst all 
patients included in this study, namely the 6th of September 2010. The ending date of the 
observation period was the last time data was observed and recorded for all patients in this study, 
namely the date on which the enquiry was granted, the 25th of April 2018. The Kaplan-Meier 
survival analysis was also performed using SPSS Version 24.0 in order to establish whether a 
difference in survival probabilities was significant. Here, three tests were applied: Log-Rank 
Test (Mantel Cox), Breslow (generalized Wilcoxon) and Tarone-Ware. The null hypothesis was 
that there was no difference in survival probabilities between the PM and control group. Results 
were significant if p<0.05. The occurring event was death. Censored patients were patients, who 
had been removed from the study over time or to whom the occurring event did not happen to, 
but it was assumed it would after the observation period had finished. Only patients to whom 







3. 1. Study Population 
3. 1. 1.  Selection of Patients for the PM Group 
The selection process of patients for the PM group is shown below in figure 1.  
Figure 1: Selection of Patients for the PM Group 
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A group of 1,627 patients eligible for the study were recruited. Three steps were taken in order to 
include and exclude patients from the study. First, 892 patients were removed because they did 
not have an echocardiography available before and after an implantation of a cardiac device. 
Second, 581 patients were removed because their echocardiographies did not meet the criteria set 
for inclusion. Lastly, 31 patients to whom no control could be matched to were excluded.  
The PM group consisted of a total of 123 patients. 42 patients (34%) had received a follow-up 
TTE within one month after implantation, 47 patients (38%) within 12 months and 103 patients 
(84%) at least one year after implantation.  








         Table 5 lists the specific data only pertaining to the PM group, such as types of implanted devices,  
         and how many leads they had. 
 
As shown in Table 5, the mean age of patients at implantation was 70 years, with a standard 
deviation of 12.5 years. About half of the patients totaling 49% (n=61) had a PM, 37% (n=46) 
had an ICD and further 14% (n=17) had received a CRT. The mean number of implantations per 
patient was one device. The mean number of leads per device per patient was two leads. The 
mean number of leads passing through the tricuspid valve was one lead. 
3. 1. 2. Selection of Patients for the Control Group 
The selection process of patients for the control group is shown below in figure 2. 
Specific Characteristics for the PM Group 
Total Number of Patients with PM included N (%) 123 (100%) 
Mean Age at Implantation of Cardiac Device in Years 70 ± 12.5 
Devices N (%):  
PM 60 (49%) 
ICD 46 (37%) 
CRT 17 (14%) 
CCM 0 
Mean Number of Implantations 1 
Mean Number of Leads per Device 2 





Figure 2 shows the selection process of the patients allocated to the control group. 
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A group of 5,611 patients eligible for the study were recruited. 199 Patients to whom no gender 
could be assigned to were removed first. Next, 1,946 patients were excluded because they had a 
total of less than four echocardiographies available. In the third step, the remaining patients were 
matched to a patient in the PM group based on gender and age, where a maximum of four 
controls could be matched to one patient with implantation. 2,852 patients were not matched and 
consecutively removed. The matches were then reevaluated and finally chosen based 
additionally on BMI and their accompanying illnesses. 476 were excluded.  
A total of 138 patients were included in the control group. 19 patients (14%) had received a 
follow-up TTE within one month after their first echocardiography, 93 patients (67%) within 12 
months and 101 patients (73%) had received a follow-up at least one year afterwards.  
3. 1. 3. Baseline Characteristics 
The baseline characteristics and demographics of the study population are summarized below in 
table 6. The mean age of patients in the PM group was 75  ±12,5 years , in the control it was 74 
±13 years. The PM group had slightly more men included (73,2%, n=90), but was not 
significantly different to the control group (73,2%, n=101. The mean BMI of 26.6 ±4.4 kg/m2 of 
the patients in the PM was similar to that of the control group, namely 26.1 ±4.3 kg/m2.  
In the majority of both groups, patients had a coronary heart disease and arterial hypertension 
diagnosed, the latter however significantly more often in the control group. In both groups, 
bypass operations, the occurrence of at least one stroke and diabetes type I or II was observed in 
less than 20% of the patients. Peripheral arterial occlusive disease and aortic valve replacements 
were observed in less than 10% of the patients in both groups. In less than 2% of the patients in 
both groups the occurrence of one pulmonary embolism was observed.  
In the control group, almost twice the amount of patients (50,7%, n=70) had received a stent 
implantation making this characteristic significantly different to that in the PM group (26,8%, 
n=33). In the PM group, roughly one third had been diagnosed with chronic renal insufficiency 

























a p-value from linear mixed model (random intercept model) hat accounts for the matched data (SPSS 24.0) 
b p-value from binary logistic mixed model (random intercept model) (STATA 15) 
c significant if p<0.05Table 6 summarizes the baseline data of the study population. 
Table 6 lists all the baseline data collected in this study for both the PM and control group. 
 
3. 1. 4. Results included for Comparisons 
When comparing the observed data in both groups, the individual control’s echocardiographies 
were only included if the matched patient in the PM group had corresponding data for the 
equivalent follow-up. Table 7 below summarizes how many echocardiographies were included 
when comparing results for all examination periods. Echocardiographies were excluded, if the 
patient’s match in the corresponding group did not have an examination in that specific time 
period.  
 
Baseline Characteristic PM Group (N=123) Control Group 
(N=138) 
P-Valuec 
Age in years, mean (SD) 75 (12,5) 74 (13) 0.449a 
Gender 
      Male 
      Female 
   
90 (73,2%) 101 (73,2%) 1.000b 
33 (26,8%) 37 (26,8%)  
BMI in kg/m2, mean (SD) 26.6 ± 4.4 26.1 ± 4.3 0.216a 
Bypass Operation 21 (17,1%) 15 (10,7%) 0.132b 
Aortic Valve Replacement 4 (3,3%) 9 (6,5%) 0.227b 
Stent Implantation 33 (26,8%) 70 (50,7%) <0.001b 
Coronary Heart Disease 72 (58,5%) 87 (63%) 0.383b 
Arterial Hypertension 88 (71,5%) 116 (84,1%) 0.001b 
Chronic Renal 
Insufficiency 
39 (31,7%) 29 (21%) 0.030b 
Diabetes Type I or II 23 (18,7%) 16 (11,6%) 0.102b 
Occurrence of at least one 
Stroke 
14 (11,4%) 19 (13,8%) 0.468b 
Peripheral Arterial 
Occlusive Disease 
10 (8,1%) 9 (6,5%) 0.798b 
Occurrence of at least one 
pulmonary embolism 

















PM Group N= total number of 
echocardiographies available 
123 42 47 103 
N= echocardiographies 
included 
123 8 34 77 
N= echocardiographies 
excluded 
0 34 13 26 
Control 
Group 
N= total number of 
echocardiographies available 
138 19 93 101 
N= echocardiographies 
included 
138 8 41 85 
N= echocardiographies 
excluded 
0 11 52 16 
a The initial examinations for the PM group were pre-implantation. The initial examination for the control group 
were the patients’ chronologically first TTE. 
Table 7 shows how many echocardiographies were included for analysis for both groups in this study. Reasons for 
exclusion are listed in sections 2.3.1. and 2.3.2.  
 
In the PM group, all echocardiographies were included for the pre-implantation observations. In 
the short-term follow-up, eight patients’ results were included, in the mid-term 34 patients’ and 
long-term 77 patient’s examinations were included.  
In the control group, all echocardiographies were included for the pre-implantation observations. 
In the short-term follow-up, eight patients’ results, in the mid-term 41 patients’ and long-term 85 
patients’ examinations were included.  
3. 2. 1. TR Classification 
In the tables 8 and 9, the median TR Grades, IQRs and p-values are displayed in each row for 
both the PM and the control group. Each column represents the follow-up period. Underneath 
each median (IQR), N (%) of patients who had an examination at that time period is listed.  The 
p-values represent whether a difference in results within a group over time was significant in 






Table 8: Median TR Grading in the PM Group in Comparison to Initial TTE 
PM Group TTE Pre-
Implantationb 
Follow-Up 




> 1 Year 
TR mediana (IQR) 1 (1) 1,5 (1) 1 (0,625) 1 (1) 
p-valuec  0.102 0.203 0.041* 
N (%) Patients 123 (100%) 8 (6,5%) 34 (28%) 77 (63%) 
a Medians were calculated using TR Grades as recorded in half steps 
b The initial examination for the PM group was the TTE before device implantation 
c p-value from Wilcoxon-Signed Rank Test; compared to initial TTE 
* significant if p<0.05 
Table 8 liststhe median (IQR) of TR Grading for the PM group. 
 
The median TR Classification remained at 1,0 for all follow-up examinations in the PM group, 
except in the short-term follow-up with 1,5. However, the IQR differed amongst follow-ups 
starting at 1 for the pre-implantation examination, then 1 at the under one month follow-up, 
0,625 at the under 12 months follow-up and lastly 1 at the long-term follow-up. The results for 
the in the long-term follow-up show a significant difference when compared to the results of the 
pre-implantation examinations for the PM group.  
Table 9: Median TR Grading in the Control Group in Comparison to Initial TTE 
Control Group Initial TTEb Follow-Up 




> 1 Year 
TR mediana 
(IQR) 0,75 (0,5) 1,0 (0,75) 0,5 (0,5) 0,5 (0,5) 
p-valuec  0.059 0.062 0.531 
N (%) Patients 138 (100%) 8 (6%) 41 (30%) 85 (62%) 
a Medians were calculated using TR Grades as recorded in half steps 
b The initial examination for the control group was the chronologically first TTE 
c p-value from Wilcoxon-Signed Rank Test, compared to initial TTE 
* significant if p<0.05 
Table 9 lists the median (IQR) TR grading for the control group. 
 
The median TR Classification for the control group was 0,75 for the initial TTE. For the 
consecutive follow-up periods the median TR Classification was 1,0 in the short-term follow-up 
and remained at 0,5 for the mid-term and long-term follow-up. The IQR remained the same at 
0,5 for all follow-up periods in the control group except in the short-term follow-up with 0,75. 





Table 10 below shows the p-values assessed for comparing the median TR Gradings of the PM 
group to those of the control group separately for each follow-up interval. The P-values in the 
bottom row indicate whether the difference between group medians was significant. 
Table 10: Median TR Grading and P-Values for PM Group versus Control Group 
 
a The initial examinations for the PM group were pre-implantation. The initial examination for the control group 
were the patients’ chronologically first TTE.  
* significant if p<0.05; assessed with a mixed-linear model on SPSS 24.0 
Table 10 lists the p-values and significance for the differences in median TR Grading for both groups.  
 
When comparing the two groups, the following observations were made concerning the TR 
Grading. First, there were marginally more controls included in this study than patients with a 
PM, however proportionately less controls received a long-term follow-up. Second, the control 
group’s median TR Grading was lower at all examination periods and was significantly lower in 
the initial examinations and in the long-term follow-ups. Third, the PM group’s TR Grading was 
significantly different within the group long-term TTEs, whereas in the control group no 
significant change long-term was observed.  
3. 2. 2. Change in Tricuspid Valve Function  
Pie Charts 1 and 2 show how many patients’ TR Grade had changed and in what manner in the 
long-term follow-up after one year in comparison to the initial TTE. Each pie chart represents 





< 1 Month 
Follow-Up 
< 12 Months 
Follow-Up 
> 1 Year 
PM Group 1,0 (1) 1,5 (1) 1,0 (0,625) 1,0 (1) 
Control Group 0,75 (0,5) 1,0 (0,75) 0,5 (0,5) 0,5 (0,5) 






In the PM group, a change in TR classification was not observed with 27 patients (35%) at the 
long-term follow up after at least one year. Of the remaining patients whose grade had changed, 
16 (21%) had improved and 34 (44%) had worsened long-term. 46 patients in the PM group 
either did not have a TTE or their TTE was not included in the long-term follow-up.  
In the control group, a change in TR classification was not observed in 43 patients (51%) at the 
long-term follow up after at least one year. Of the remaining patients whose grade had changed, 
19 (22%) had improved and 23 (27%) had worsened long-term. 53 patients in the PM group 
either did not have a TTE or their TTE was not included in the long-term follow-up  
Proportionately, more patients worsened in TR Grading in the PM group over time. However, 
more patients remained the same in TR Grading in the control group over time. A similar portion 
of patients improved in TR Grading in both groups. 
3. 2. 3. How the Tricuspid Valve Function changed in the PM Group 
Bar graph 1 below shows how the TR gradings were distributed amongst the pre-implantation 
examinations (left column) and the long-term follow-up (right column) for the PM group. The 
arrows represent who changed and in what manner for each classification, the number of patients 
is labelled accordingly. In this figure, gradings were summarized in the common TR 
classification system as 0, I, II, III for overview purposes.  
Figure 4: a pie chart showing how many patients’ TR Grading 
in the control group had worsened, improved or remained 
























improved remained same worsened 
Figure 3: Change Pacemaker Group 
Figure 3: a pie chart showing how many patients’ TR Grading 
in the pacemaker group had worsened, improved or remained 





In the pre-implantation TTEs, 6% (n=7) of patients had a TR grade 0. Of these patients, two 
patients (29%) worsened by one grade and one patient worsened by three grades. (14%). Four of 
these patients (57%) did not have a long-term follow up. 
69% (n=85) of the patients had a TR grade of I initially.  Of these patients, one (1%) improved 
by one grade, 41 (48%) remained the same, 10 (12%) worsened by one grade and two (2%) 
patients worsened by two grades. 31 of these Patients (36%) did not have a long-term follow-up. 
21% (n=26) of the patients had a TR Grade of II initially. Of these patients, 10 (38%) improved 
by one grade, six (23%) remained the same and two (8%) patients worsened by one grade. Of 
these patients, 8 (31%) did not have a long-term follow-up.  
4% (n=5) of the patients had a TR Grade of III initially. Of these patients, one (20%) improved 
by one grade and one (20%) remained the same. Three of these patients (60%) did not have a 
long-term follow up. 
Thus, the distribution of TR grades amongst the 77 echocardiographic long-term follow-ups after 
at least one year after implantation in the PM group was: 1% (n=1) had a TR 0°, 69% (n=53) had 















Figure 5: Bar Graph showing how TR Grading Changed Long-Term in the PM Group 
Figure 5 is a bar graph depicting the distribution of TR Grading in the PM group during the initial TTE and how it 
changed in the long-term follow-up. 
3. 2. 4. How the Tricuspid Valve Function changed in the Control Group 
Bar graph 2 below shows how the TR gradings were distributed amongst the initial examinations 
(left column) and the long-term follow-up (right column) for the control group. The arrows 
represent who changed and in what manner for each classification, the number of patients is 
labelled accordingly. In this figure, gradings were summarized in the common TR classification 
system as 0, I, II, III for overview purposes.  
In the initial TTEs, 12% (n=17) of the controls had a TR grade 0. Of these patients, three (18%) 
remained the same and nine (53%) worsened by one grade. Five patients (29%) did not have a 
long-term follow-up.  
73% (n=101) of the controls had a TR grade I initially. Of these patients, 57 (56%) remained the 






11% (n=15) of the controls had a TR grade II initially. Of these patients, four (26,6%) improved 
by one grade and five (33,3%) remained the same. Six of these patients (40%) did not have a 
long-term follow up.  
4% (n=5) of the controls had a TR grade III initially. Of these patients, one (20%) improved by 
one grade and two (40%) remained the same. Two patients (40%) did not have a long-term 
follow up. 
Thus, the distribution of TR grades amongst the total 85 echocardiographic long-term follow-ups 
in the control group was: 4% (n=3) had TR 0°, 82% (n=70) had TR I°, 12% (n=10) had TR II° 
and lastly 2% (n=2) had TR III°.  
Figure 6: Bar Graph showing how TR Grading Changed Long-Term in the Control Group 
Figure 6 shows a bar graph depicting the distribution of TR Grading in the control group during the initial TTE and 





3. 3. Other echocardiographic Values 
3. 3. 1. TR Vmax 
Tables 11 and 12 below display the mean TR Vmax m/s and standard deviation for each group 
separately. Each column represents the results for the follow-up period consecutively from right 
to left. The rows represent the mean values, p-values and n (%) patients for each follow-up 
period. The p-values represent whether a difference in results within a group over time were 
significant in comparison to the initial TTE. 
Table 11: Mean TR Vmax m/s in the PM Group in Comparison to the Initial TTE 
PM Group TTE Pre-Implantationa 
Follow-Up 




> 1 Year 
TR Vmax m/s 
mean (SD) 2,59 (0,72) 2,8 (0,27) 2,71 (0,59) 2,66 (0,54) 
p-valueb  0.803 0.080 0.619 
N (%) Patients 123 (100%) 8 (6,5%) 34 (28%) 77 (63%) 
aThe initial examination for the PM group was the TTE before device implantation 
bp-value from Wilcoxon-Signed Rank Test, compared to initial TTE 
* significant if p<0.05 
Table 11 lists the mean TR Vmax for the PM group. 
 
The mean TR Vmax in the pre-implantation examinations for the PM group was 2,59 ±0,72 m/s. 
Within the first month after implantation it was 2,8 ±0,27 m/s. Within 12 months after 
implantation the mean lay at 2,71 ±0,59 m/s. In the long-term follow-ups, the mean TR Vmax 
for the PM group was 2,66 ±0,54 m/s. The changes in TR Vmax over time were not significant 
within the PM group. 
Table 12: Mean TR Vmax m/s in the Control Group in Comparison to the Initial TTE 




> 1 Year 
TR Vmax m/s 
mean (SD) 2,56 (0,70) 2,35 (0,50) 2,61 (0,60) 2,60 (0,60) 
p-valueb  0.063 0.213 0.490 
N (%) Patients 138 (100%) 8 (6%) 41 (30%) 85 (62%) 
aThe initial examination for the control group was the chronologically first TTE 
bp-value from Wilcoxon-Signed Rank Test, compared to initial TTE 
* significant if p<0.05 
Table 12 lists the mean TR Vmax for the PM group. 
 
The mean TR Vmax for the control group in the initial examinations was 2,56 ±0,70 m/s. In the 





months afterwards, the mean lay at 2,61 ±0,60 m/s. In the long-term follow-up, the mean TR 
Vmax for the control group was 2,60 ±0,60 m/s.  
The mean TR Vmax increased significantly within the mid-term follow-up, however no 
significant change was observed long-term.  
Table 13 below shows the p-values when comparing the mean TR Vmax m/s of the PM group to 
those of the control group separately for each follow-up interval.  






< 1 Month 
Follow-Up 
< 12 Months 
Follow-Up 
> 1 Year 
PM Group 2,59 ±0,72 2,8 ±0,27 2,71 ±0,59 2,66 ±0,54 
Control Group 2,56 ±0,70 2,35 ±0,50 2,61 ±0,60 2,60 ±0,60 
p-value 0.673 0.014* 0.469 0.530 
a The initial examinations for the PM group were pre-implantation. The initial examination for the control group 
were the patients’ chronologically first TTE 
* significant if p<0.05; assessed with a mixed-linear model on SPSS 24.0 
Table 13 lists the different mean TR Vmax for both groups and whether these differences were significant. 
 
The mean TR Vmax was significantly higher in the exposure group during the short-term follow-
ups. No other differences between the groups were significant. 
Line graph 1 shows the mean values and their standard deviations for the TR Vmax observed in 
the PM and the control group. The means for each follow-up period are displayed. The x axis 











Figure 7: TR Vmax (m/s) Mean and Standard Deviation 
 
* significant if p<0.05 
Figure 7 shows a line graph marking the mean TR Vmax of the PM in comparison to the PM group. 
 
When comparing the two groups, the following observations were made concerning the TR 
Vmax m/s. The mean TR Vmax of the PM group was greater at every follow-up period. 
However, the PM group had a significantly higher TR Vmax only short-term. For both the PM 
and control group, no significant change was observed within each group long-term. 
3. 3. 2. TAPSE 
Tables 14 and 15 display the mean TAPSE mm and standard deviation for each group separately. 
Each column represents the results for the follow-up period consecutively from right to left. The 
rows represent the mean values, p-values and n (%) patients for each follow-up period. The p-
values represent whether a difference in results within a group over time were significant in 
comparison to the initial TTE. 
Table 14: Mean TAPSE mm in the PM Group in Comparison to the Initial TTE 
PM Group TTE Pre-Implantationa 
Follow-Up 




> 1 Year 
TAPSE mm 


















p-valueb  0.575 0.861 0.803 
N (%) Patients 123 (100%) 8 (6,5%) 34 (28%) 77 (63%) 
aThe initial examination for the PM group was the TTE before device implantation 
bp-value from Wilcoxon-Signed Rank Test, compared to initial TTE 
* significant if p<0.05 
Table 14 lists the mean TAPSE for the PM group.  
 
 
The mean TAPSE in the pre-implantation examinations for the PM group was 21,72 ±5,87 mm. 
Within the one-month follow-up, the mean was 19,7 ±8,0 mm. Within the 12-month follow-up, 
the mean was 22,18 ±5,16 mm. The mean TAPSE for the PM group in the long-term follow-ups 
was 21,57 ±5,54 mm. No significant change in the mean TAPSE within the PM group was 
observed. 
Table 15: Mean TAPSE mm in the Control Group in Comparison to the Initial TTE 




> 1 Year 
TAPSE mm 
mean (SD) 23,75 (4,89) 23,22 (4,66) 24,55 (5,50) 23,45 (4,47) 
p-valueb  0.397 0.560 0.620 
N (%) Patients 138 (100%) 8 (6%) 41 (30%) 85 (62%) 
aThe initial examination for the PM group was the TTE before device implantation 
bp-value from Wilcoxon-Signed Rank Test, compared to initial TTE 
* significant if p<0.05 
Table 15 lists the mean TAPSE for the control group 
The mean TAPSE for the control group in the initial examinations was 23,75 ±4,89 mm. The 
mean in the one-month follow-up was 23,22 ±4,66 mm. The mean in the 12-month follow-up 
was 24,55 ±5,50 mm. The mean TAPSE for the control group in the long-term follow-ups was 
23,45 ±4,47 mm. No significant change in mean TAPSE was observed within the control group. 
Table 16 below shows the p-values when comparing the mean TAPSE mm of the PM group to 
those of the control group separately for each follow-up interval. 






< 1 Month 
Follow-Up 
< 12 Months 
Follow-Up 
> 1 Year 
PM Group 21,72 ±5,87 19,7 ±8,0 22,18 ±5,16 21,57±5,54 
Control Group 23,75 ±4,89 23,22±4,7 24,55 ±5,50 23,45 ±4,47 
p-value 0.002* 0.211 0.043* 0.018* 
a The initial examinations for the PM group were pre-implantation. The initial examination for the control group 
were the patients’ chronologically first TTE 





Table 16 lists the different mean TAPSE for both groups and whether these differences were significant. 
 
 
Additionally, Line graph 2 shows the mean values and their standard deviations for the TAPSE 
observed in the PM and the control group and summarized in Table 16. The means for each 
follow-up period are displayed. The x axis represents the time periods, the y axis represents the 
TAPSE measurement in mm.  
Figure 8:  TAPSE (mm) Mean and Standard Deviation 
 
* significant if p<0.05 
Figure 8 shows a line graph that depicts the different mean TAPSE for both groups. 
When comparing the two groups, the following observations were made regarding the TAPSE. 
First, no changes within both groups were significant. However, the mean TAPSE of the control 
group was greater at every follow-up period.  The control’s TAPSE was significantly greater in 
the initial examinations, in the mid-term and in the long-term follow-up. 
3. 3. 3. LVEF 
Tables 17 and 18 display the mean LVEF % and standard deviation for each group separately. 
Each column represents the results for the follow-up period consecutively from right to left. The 
rows represent the mean values, p-values and n (%) patients for each follow-up period. The p-
values represent whether a difference in results within a group over time were significant in 























Table 17: Mean LVEF% in the PM Group in Comparison to the Initial TTE 
PM Group TTE Pre-Implantationa 
Follow-Up 




> 1 Year 
LVEF % Mean (SD) 46,6 (19,6) 44,2 (13,7) 50,7 (17,1) 48,4 (15,9) 
p-valueb  0.109 0.120 0.344 
N (%) Patients 123 (100%) 8 (6,5%) 34 (28%) 77 (63%) 
aThe initial examination for the PM group was the TTE before device implantation 
bp-value from Wilcoxon-Signed Rank Test, compared to initial TTE 
* significant if p<0.05 
Table 17 lists the mean LVEF for the PM group for all examination periods. 
 
The LVEF for the PM group averaged at 46,6 ±19,6% before implantation. The mean LVEF in 
the first two follow-ups was 44,7 ±15,0% and 50,7 ±17,1%. However, it averaged at 48,4 
±15,9% in the long-term follow up being slightly larger than pre-implantation. Within the PM 
group, the average LVEF did not significantly change by the end of this study. 
Table 18: Mean LVEF% in the Control Group in Comparison to the Initial TTE 




> 1 Year 
LVEF % Mean (SD) 59,1 (13,7) 54,78 (15,3) 60,0 (11,9) 62,9 (9,5) 
p-valueb  0.008* 0.022* 0.188 
N (%) Patients 138 (100%) 8 (6%) 41 (30%) 85 (62%) 
aThe initial examination for the control group was the chronologically first TTE 
bp-value from Wilcoxon-Signed Rank Test, compared to initial TTE 
* significant if p<0.05 
Table 18 lists the mean LVEF for the control group for all follow-up periods. 
 
The controls’ initial mean LVEF was 59,1 ±13,7%, followed by 54,78 ±15,3%, 60,0 ±11,9% and 
lastly averaged at 62,9 ±9,5 % at the long-term follow-up. LVEF averaged significantly less in 
the first follow-up (p=0.008) and improved again significantly in the second follow-up (p=0.022) 
when compared to the initial TTE.  
Table 19 below shows the p-values assessed when comparing the mean LVEF % of the PM 
group to those of the control group separately for each follow-up interval. 






< 1 Month 
Follow-Up 
< 12 Months 
Follow-Up 
> 1 Year 
PM Group 46,6 ±19,6 44,2 ±13,7 50,7 ±17,1 48,4 ±15,9 





p-value <0.001* 0.004* 0.001* <0.001* 
a The initial examinations for the PM group were pre-implantation. The initial examination for the control group 
were the patients’ chronologically first TTE 
* significant if p<0.05; assessed with a mixed-linear model on SPSS 24.0 
Table 19 lists the different mean LVEF for both groups and whether these differences were significant.  
 
The mean LVEF was significantly greater in the control group at every follow-up period.  
Line graph 3 shows the mean values and their standard deviations for LVEF observed in the PM 
and the control group. The means for each follow-up period are displayed. The x axis represents 
the time periods, the y axis represents the LVEF measurement in %. 
Figure 9: LVEF % Mean and Standard Deviation  
 
* significant if p<0.05 
Figure 9 shows a line graph depicting the mean LVEF for both groups. 
 
 
When comparing the PM and control group, the following observations were made regarding 
LVEF. Both group’s LVEF worsened significantly short-term. The control groups’ mean LVEF 
improved significantly mid-term again.  
The control group’s mean LVEF was significantly greater than that of the PM group at every 
time period. However, there was no significant change long-term in both groups.  
3. 3. 4. Right Atrium Volume 
Tables 20 and 21 display the mean RA volume in ml and standard deviation for each group 
separately. Each column represents the results for the follow-up period consecutively from right 























period. The p-values represent whether a difference in results within a group over time were 
significant in comparison to the initial TTE. 
Table 20: Mean RA Volume (ml) in the PM Group in Comparison to the Intial TTE 
PM Group TTE Pre-Implantationa 
Follow-Up 




> 1 Year 
RA Volume (ml) 
Mean (SD) 51,7 ±24,9 49,8 ±33,8 54,8 ±33,5 62.3 ±37,7 
p-valueb  0.917 0.480 0.054 
N (%) Patients 123 (100%) 8 (6,5%) 34 (28%) 77 (63%) 
aThe initial examination for the PM group was the TTE before device implantation 
bp-value from Wilcoxon-Signed Rank Test, compared to initial TTE 
* significant if p<0.05 
Table 20 lists the mean RA volume for the PM group for all follow-up periods. 
 
The mean RA volume in the PM group’s initial examinations was 51,7 ±24,9ml, followed by 
49,8 ±33,8ml short-term, 54,8 ±33,5ml mid-term and averaged at 62.3 ±37,7ml in the long-term 
follow-ups. There was no significant change in RA volume in the PM group over time.  
Table 21: Mean RA Volume (ml) in the Control Group in Comparison to the Intial TTE 




> 1 Year 
RA Volume (ml) 
Mean (SD) 44,0 ±30,1 75,7 ±58,7 47,1 ±29,5 51,7 ±44,5 
p-valueb  0.465 0.657 0.821 
N (%) Patients 138 (100%) 8 (6%) 41 (30%) 85 (62%) 
aThe initial examination for the PM group was the TTE before device implantation 
bp-value from Wilcoxon-Signed Rank Test, compared to initial TTE 
* significant if p<0.05 
Table 21 lists the mean RA volume for the control group for all examination periods. 
 
The control group’s initial average RA volume was 44,0 ±30,1ml. Within the first month 
afterwards the mean lay at 75,7 ±58,7ml, was 47,1 ±29,5ml within one year afterwards and 
averaged at 51,7 ±44,5ml in the long-term follow-up. The was no significant change in RA 
volume in the control group over time. 
Table 22 below shows the p-values assessed when comparing the mean RA volume in ml of the 
PM group to those of the control group separately for each follow-up interval. 










< 1 Month 
Follow-Up 
< 12 Months 
Follow-Up 
> 1 Year 
PM Group 51,7 ±24,9 49,8 ±33,8 54,8 ±33,5 62.3 ±37,7 
Control Group 44,0 ±30,1 75,7 ±58,7 47,1 ±29,5 51,7 ±44,5 
p-value 0.018* 0.207 0.482 0.101 
a The initial examinations for the PM group were pre-implantation. The initial examination for the control group 
were the patients’ chronologically first TTE 
* significant if p<0.05; assessed with a mixed-linear model on SPSS 24.0 
Table 22 lists the different mean RA volume for both groups and whether these differences were significant.  
 
 
Line graph 4 shows the mean values and their standard deviations summarized in table 22 for 
RA volume observed in the PM and the control group. The means for each follow-up period are 
displayed. The x axis represents the time periods, the y axis represents the RA volume 
measurement in ml. 
Figure 10: RA Volume (ml) Mean and Standard Deviation 
* significant if p<0.05 
Figure 10 shows a line graph markig the mean RA volume for both groups. 
 
When comparing the two groups, the PM group’s mean RA volume was only significantly 























3. 3. 5. All Echocardiographic Values   
Table 23 summarizes the median values, IQRs, mean values, standard deviations and absolute 
frequencies for all of the echocardiographic data observed in this study. The Table lists all data 
for both the PM as well as the control group. Each column represents the specific follow-up 
period. Each row represents the data for the PM and control group alternately.  
The values described in this table from top to bottom are: TR Grade, TR Vmax in m/s, TAPSE in 
mm, LVEF in %, the recorded SPAP in mmHG, the calculated SPAP in mmHg, CVP in mmHG 
and lastly how often a widened vena contracta had been observed.   
The values marked with an asterisk are the values that were significantly different (p<0.05) when 
comparing the results between the PM and control group.  
Table 23: Summary Table for all other Echocardiographic Values for the PM and Control Group 
a PM Group N=123; Control Group N=138 
b The initial examination for the PM group was the TTE before device implantation; the initial examination for the 
control group was the chronologically first TTE 












PISA (mm)  
mean (SD) 
PM 5,4 (1,8) 5,7 (2,0) 6,2 (2,6) 5,4 (1,9) 




PM 36,6 (11,6) 35,4 (9,5) 36,5 (10,2) 35,3 (9,7) 





PM 34,2 (14,2) 37,4 (6,9) 36,5 (12,1) 35,0 (11,1) 
Control 33,4 (15,7) 29,8 (10,6)* 34,1 (14,2) 33,0 (13,2) 
CVP (mmHg) 
mean (SD) 
PM 5,5 (1,7) 5,8 (2,0) 5,7 (1,7) 5,7 (2,1) 




PM 5,6 (1,6) 5,4 (2,8) 5,2 (2,1) 5,0 (1,7) 





Table 23 shows the mean values for other echocardiographic values used to indirectly asses TR. Here the averages 
of the PM and control group are compared statistically to one another and marked accordingly if significantly 
different. 
 
The values for the median TR Grade, mean TR Vmax, mean TAPSE and mean LVEF are 
described in the section above.  
The mean PISA in the PM group hardly differed within the course of this study. Initially it was 
5,4 ±1,8 mm, in the first follow-up it was 5,7 ±2,0 mm, mid-term it was 6,2 ±2,6 mm, and lastly 
averaged at 5,4 ±1,9 mm in the long-term follow-up. The control group’s initial mean PISA was 
5,2 ±2,0 mm, was 7,3 ±3,0 mm short-term, was 7,0 ±2,7mm mid-term and was lastly 5,3 ±2,1 
mm in the long-term follow-up. The differences between both groups were not significant at any 
examination period.  
The mean recorded SPAP for the PM group differed slightly throughout follow-ups. The initial 
mean was 36,6 ±11,6 mmHg, followed by 35,4 ±9,5 mmHg, 36,5 ±10,2 mmHg and averaged at 
35,3 ±9,7 mmHg in the long-term follow up. The lowest mean recorded SPAP was observed in 
the one-month follow up for both groups. The control group’s initial mean recorded SPAP was 
34,2 ±14,0 mmHg, followed by 30,3 ±9,4 mmHg, 32,7 ±15,8 mmHg and averaged at 32,4 ±11,4 
mmHg. The controls’ recorded SPAP was on average lower than that of the PM group at each 
follow-up and but not significantly lower at any follow up.  
The mean calculated SPAP for the PM group differed throughout follow-ups as well. The initial 
mean was 34,2 ±14,2 mmHg, followed by 37,4 ±6,9 mmHg, 36,5 ±12,1 mmHg and averaged at 
35,0 ±11,1 mmHg long-term. The lowest mean calculated SPAP was observed initially in the 
PM group, and at the one-month follow up for the control group. The control group’s initial 
calculated SPAP mean was 33,4 ±15,7 mmHg, followed by 29,8 ±10,6 mmHg, 34,2 ±14,2 
mmHg and averaged at 33,0 ±13,2 mmHg in the long-term follow-up. The controls’ calculated 
SPAP was on average lower than that of the PM group at each follow-up. The control group’s 
lower mean calculated SPAP was only significant in the short-term follow-up. 
The mean CVP for the PM group initially was 5,5 ±1,7 mmHg, followed by 5,8 ±2,0 mmHg, 5,7 
±1,7 mmHg and lastly 5,7 ±2,1 mmHg. The control group’s mean CVP initially was 5,4 ±1,7 
mmHg, followed by 6,7 ±3,5 mmHg, 5,3 ± 1,2 mmHg and lastly 5,1 ±0,8 mmHg. The control 





The mean vena contracta width in the PM group initially was 5,6 ±1,6mm, was 5,4 ±2,8mm 
short-term, was 5,2 ±2,1 mm mid-term and 5,0 ±1,7 mm in the long-term follow-up. The control 
group’s mean vena contracta width was initially 5,1 ±1,6 mm, followed by 9,3 ±3,8 mm short-
term, was 5,8 ±1,8 mm mid-term and was lastly 6,2 ±7,1 mm long-term. The differences 
between the two groups were not significant at any examination period. 
3.4. Tests for Significance Differences 
In order to establish whether the differences in medians and means between the PM and control 
group were statistically significant, a mixed linear model for paired variables on SPSS Version 
24.0 was performed. Here the results of both groups were compared to each other for each 
follow-up period. Table 24 below summarizes the output of each test. Each column represents 
the different follow-up periods. Each row represents the characteristic analyzed with the 
according p-value. In this Test, the TR classification used was as recorded for the study in half 
steps.  
Table 24: P-Values for each Variable PM versus Control 
* significant if p<0.05; assessed with a mixed-linear model on SPSS 24.0 
a The initial examinations for the PM group were pre-implantation. The initial examination for the control group 
were the patients’ chronologically first TTE.  
b TR Grading in this Test was kept in half steps as recorded in this study.  
Variable Initial Examinationa 
Follow-Up 
< 1 Month 
Follow-Up 
< 12 Months 
Follow-Up 
> 1 Year 
TR Gradingb 0.024* 0.140 0.072 <0.001* 
TR Vmax (m/s) 0.673 0.014* 0.469 0.530 
TAPSE (mm) 0.002* 0.211 0.043* 0.018* 
LVEF (%) <0.001* 0.004* 0.001* <0.001* 
RA Volume (ml) 0.018* 0.353 0.283 0.101 
PISA (mm) 0.613 0.220 0.559 0.877 
SPAP recorded 
(mmHg) 0.175 0.188 0.197 0.112 
SPAP calculated 
(mmHg) 0.647 0.035* 0.367 0.287 
CVP (mmHg) 0.754 0.612 0.276 0.017* 
Vena Contracta 





Table 24 summarizes all the p-values assessed for comparing the specific echocardiographic data of the PM and the 
control group and marked accordingly if significant. 
 
The difference in TR grading between the PM and control group was statistically significant in 
the initial Examination (p= 0.021) and within the long-term follow-up (p=<0.001). The 
differences in mean TR Vmax were significant in the short-term follow-up (p=0-.014). The 
difference in TAPSE observations between both groups was statistically significant in the initial 
examination (p=0.001), in the 12-motnh follow-up (p=0.009) and in the long-term follow-up 
(p=0.001). The difference in LVEF observations between both groups was statistically 
significant in all examination periods (p= <0.001, 0.003, <0.001 and <0.001). The difference in 
RA Volume was significant in the initial examination (p=0.018). The differences in PISA were 
not significantly different at any examination period. The difference in SPAP as recorded by 
examiners was not statistically significant in any examination period. The difference in SPAP as 
calculated in this study was statistically significant in the short-term follow-up (p=0.035). The 
difference in CVP observation for both groups was statistically significant in the long-term 
follow-up (p=0.017). The differences in vena contracta width were not significantly different at 
any examination period. 
3. 5. Survival 
3. 5. 1. Overall Survival 
The enquiry was made for all 261 patients included in this study, namely the 123 patients in the 
PM group and the 138 Patients in the control group. On the date of the granted enquiry, 
information was provided for a total of 226 (87%) patients. Of these 226 patients, 71 (31%) had 
been registered as deceased. For the remaining 35 (13%) no information was provided.  
Bar graph 3 below shows how many people were registered as alive, deceased and for how many 
patients no information was provided for both the PM group and control group separately on the 
date of the granted enquiry. Reasons for why no information could be provided are described in 
section 2.7.2. In the bar graph below, the X axis represents the group and information provided 
accordingly. The y-axis represents the percentage of patients pertaining to each group. Each 







Figure 11: Overall Survival of PM and Control Group 
 
Figure 11 depicts the absolute amount of patients in this study who had been registered as deceased, alive or to 
whom no information was provided for in 2018 in Berlin Germany, enquired at the Landesamt für Bürger- und 
Ordnungsangelegenheiten Berlin, Germany (State Office for Residents’ and Regulatory Affairs).  
 
In the PM group, 52,8 % (N=65) of the patients were registered as alive, 32,5% (N=40) as 
deceased and for 14,6% (N=18) no information was provided. In the control group, 66,7% 
(N=92) of the patients were registered as alive, 21,0% (N=29) as deceased and for 12,3% (N=17) 
no information was provided. Proportionately, less people were registered as alive and more as 
deceased in the PM group.  
3. 5. 2. Kaplan-Meier Estimate 
Figure 3 displays a Kaplan-Meier estimate. The graph shows two functions, each one 
representing the PM or control group. The x-axis represents the time in years. The y axis 
represents the cumulative survival probability of the patients. Each cross on a line represents 
when a single or multiple patients were censored. The graph also shows that the observation 












































Figure 12:  Kaplan-Meier Estimate 
 
Figure 3 shows the Kaplan Meier Estimate as a cumulative survival function over time. It reveals that the PM group 
had a significantly lower cumulative survival probability. 
 
Additionally, the output results from SPSS are shown below in Table 25. 
Table 25: Output SPSS Kaplan-Meier 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 5.770 1 .016 
Breslow (Generalized 
Wilcoxon) 
6.041 1 .014 
Tarone-Ware 5.926 1 .015 
Test of equality of survival distributions for the different levels of Group (Factor) 
 
Table 25 is an original output calculated in this study and lists the specific information for the significance 
calculation. 
 
p= 0.016 (Log-Rank) 
p= 0.014 (Breslow) 





The Kaplan-Meier survival curve shows that the patients in the PM group had a significantly 
lower estimated cumulative survival probability of roughly 61%. The control group’s estimated 
cumulative survival probability was around 78%. The three tests used to analyse the difference 
in cumulative survival probabilities show that the difference was significant (p=0.016, p= 0.014, 
p=0.015). Censored patients only occurred at the ending date of the observation, as the study was 
conducted retrospectively and no patients dropped out during the observation period.  
Discussion 
4. 1. Major Findings 
The findings in this study suggest that the right and left heart function in patients, who had 
received a cardiac rhythm device, remained stable. The observations infer that TR did not 
principally worsen after device implantation. The findings pertaining to TAPSE, RA volume and 
CVP indicate that patients with a cardiac device generally had a worse right heart systolic 
function than patients without one. However, all parameters did not show great alteration over 
time for both groups and thus this implies that the presence of an RV lead did not primarily 
worsen TV function. Including the findings additionally pertaining to LVEF, this study indicates 
that patients with a cardiac rhythm device were generally more ill from the onset than patients 
without a device.  
The results in this study also suggest that the implantation of a PM or similar device decreased a 
patient’s cumulative life expectancy.  
4. 1. 1. Misleading Changes in TR Grading 
The median TR grading in the PM group, which consisted of patients that had one of the three 
cardiac devices (PM, ICD, CRT) included in this study implanted, was significantly worse in the 
long-term follow-up, however it was to begin with as well. Additionally, the difference in 
medians was minimal in both periods. When looking at the changes within the PM group, the 
median long-term TR grade was calculated as significantly different, however the actual median 
number and IQR remained the same. This could be explained as that the distribution of grading 
changed over time, which can be observed in the pie charts 1 and in the bar graph 1. On the one 
hand, more patients’ grading the PM group worsened than in the control, but on the other within 





Additionally, as seen in Figure 5 and 6, the way that patients’ grading had changed by the end of 
this study did not reveal any further findings. There was no trend recognizable in both groups. It 
seems as though generally there was more shifting within the pacemaker group, but this instead 
made any generalizations less discernible. Furthermore, when directly comparing the bars for 
each group accordingly, it became clear that the final distributions were not divergent.   
4. 1. 2. Direct Effects were not apparent 
TR Vmax, PISA and vena contracta are all parameters that directly measure a value at the TV 
and its opening area.  For all three of these in this study, there were no significant changes within 
the group observed, and only one minor difference regarding TR Vmax short-term. Even though 
TR Vmax was greater in the PM group, the only short-term significant difference was more 
likely due to statistical reasons, namely the small number of echocardiographies included in that 
time period. These findings imply that a RV lead did not impact direct parameters of TV 
function. 
4. 1. 3. Indirect Effects were not apparent 
In both the PM and control group, the RA volume and CVP revealed the same pattern. For both 
parameters, there was no change detectable within the groups, except that RA volume was 
significantly greater initially and CVP was significantly lower in the long-term examination in 
the control group. The RA volume determines RA pressure, thus also determines CVP70. If there 
were a true hemodynamic relevance, then both values would change more synchronously to each 
other.  
The other parameters pertaining to right heart function in this study, such as the TAPSE or 
SPAP, do not show a worsened right heart function in either groups. This furthermore supports 
the assumption that the indirect TV parameters of a greater CVP and RA volume in the PM 
group were less likely due to an RV lead.  
4. 1. 4. Baseline Characteristics could explain low LVEF 
The PM group included significantly more patients with chronic renal insufficiency and the PM 
group had a significantly lower LVEF. One consideration is that a possible indication for 
implanting an ICD is low LVEF for primary prophylaxis, but patients who qualify for a 
secondary prophylactic implantation often have a low LVEF as well37. This would explain why 





characteristics chronic renal insufficiency and low LVEF in the PM group could correlate with 
each other regarding cardiorenal syndromes. Cardiorenal syndromes describe conditions, in 
which the low cardiac output over time has a negative effect on the renal function through 
several mechanisms, such as a constantly activated renin-angiotensin system and the production 
of natriuretic peptides71. It is not distinguishable, which organ is affected first, but it is a viable 
explanation for why these two characteristics were significant in the PM group.  
In this study, LVEF was not affected by device implantation either. Alizadeh et al. conducted a 
study in 2011 with 115 patients who all had a normal LVEF at baseline. The study showed 
similar to this one that TR increased after PM implantation and that it did not have an effect on 
the left heart function72.  
4. 2. Comparison to Previous Studies 
It is important to compare the findings in this study to the setting in current literature. There are 
several studies that concurred with the results of this study. A study conducted in 2009 by 
Klutstein et al. found that in patients with a PM and TR Grading of II or worse, the majority did 
not change in TR over time73. In 2012, Eleid et al. conducted a study in which TR was observed 
before and after the implantation of a cardiac device in patients with a bioprosthetic valve in 
comparison to a control group. Eleid et al. also found that the pacing leads did not have an effect 
on TR74.  
Furthermore, there are studies that demonstrated similar results pertaining to mortality, but they 
have to be compared critically due to different methodological procedures. Between 2002 and 
2009, Höke et al. conducted a retrospective study at the Leiden University Medical Center and 
found that if an increase in TR Grading of over two classifications occurred, the long-term 
prognosis of a patient decreased. Contrary to this study, Höke et al. excluded patients who had 
received valve surgery or had HF and classified patients’ TR Grade systematically based upon 
echocardiographic findings. These exclusions allowed a stronger correlational analysis. Höke at 
al. were able to show that a RV-Lead could have induced a strong decrease in tricuspid valve 
function and that the prognosis of a patient was negatively influenced by it75.  
There are also authors who contrarily suggested that the implantation of a cardiac device did 
have an effect on the TV. In 2014, Sadeddrini et al. conducted a retrospective study with 155 
patients and found that the implantation of a cardiac device significantly worsened TR compared 





significantly change and that the implantation with a CRT did not influence TR76. Arabi et al. 
conducted a prospective study similar to the current one in 2015. 41 patients with either a PM, 
ICD, or CRT had TTE examinations at one, six and 12 months after implantation. Arabi et al. 
found that TR increased significantly throughout all groups with a majority of 70.8% of all 
patients by at least one grade long-term. RV ejection fraction seemed to worsen after the 
implantation of a device. However, TR and general RV parameters showed no significant 
differences amongst different types of devices77.  
Furthermore, a study conducted by Kim et al. with 248 patients who had either a PM or ICD 
implanted showed that not only TR increased overall, but that the TR function worsened 
significantly more in patients with an ICD63. These results echo the observations made in this 
study.  
In addition, reviews published by Al-Mohaissen in 2012 and Chang et al. in 2017 came to the 
same conclusion and stated that TR can be induced by cardiac device lead placement78,79.  
4. 3. Possible Mechanisms that induce Tricuspid Regurgitation  
4. 3. 1. Mechanical Interference 
There are several possible explanations as for why a patient could develop TR after the 
implantation of a cardiac device. One proposition is that the PM lead physically interferes with 
the TV leaflets in various ways. Saran et al. conducted a study in which 622 patients who had a 
PM, a TR of moderate to severe TR and had received TV surgery were examined 
retrospectively. The patients were divided into two groups: PM induced and PM associated TR. 
The first meaning that the PM lead had definitely caused TR by “restriction of the mobility of 
otherwise normal-appearing leaflets or subvalvular apparatus, scarring or fusion of leaflets to 
each other, leaflet adherence to the leads, leaflet perforation or chordal entrapment”80; the latter 
meaning it had not been directly caused by the lead. 42% of the patients had induced TR, 58% of 
the patients associated TR. The main cause for induced TR was restricted leaf mobility by the 
lead, the main cause for associated TR was functional TR80. Lin et al.81 , Uehara et al.82 and 
Mediratta et al.83 are also examples of studies who found that TR Grading worsened after PM 
implantation due to lead intervention with the TV. 
 Saran et al. found that almost half the patients with a PM and a TR of minimum Grade II had a 





was more common80. This suggests that TR in paced patients is not obligatory, but if it does 
occur lead impediment is most likely the cause.  
4. 3. 2. Exact Location of Leads 
Some authors suggest that the exact placement of the lead within the TV or the specific leaflet 
affected by the lead plays a defining role. A case study published by Wardell et al. for example, 
identified the posterior leaflet as the most commonly affected leaflet causing TR84. Concerning 
the topography of the lead tip there are competing voices. For example, Wang et al. found that 
TR was observed more often if the lead tip was placed in the right ventricular outflow tract than 
in the right ventricular apex85. Krupa et al. conducted a study including 86 patients and did not 
discover a difference in TR  between tip lead placement in the right ventricular outflow tract, 
apex or para-apex area86. It is debatable whether the lead tip and the leaflet affected are to be 
treated as independent, as the tip placement ultimately predetermines where the lead will trespass 
the TV.  
4. 3. 3. Other Causes for TR 
Various case studies have described other rare causes of TR after PM implantation, such as the 
PM lead perforating the papillary muscle87, lead perforation of the TR Leaflets or chordae82,88 
Not all complications are based on short-term effects. In an earlier paper by Becker et al. three 
case reports were published describing the “thrombotic encapsulation” of a PM lead after two 
weeks and the “fibrous encapsulation” of PM leads after eight and 12 months89. This implies that 
additional, more long-term effects, influence the TV function indirectly.  
In 2010 the European Journal of Echocardiography published a study conducted by Vaturi et al. 
The study included 23 patients with a permanent pacemaker and a normal LVEF. The patients 
were divided into an active and non-active pacing group. Echocardiographic follow-ups were 
performed after the PM reprogramming. Although the study included few patients, Vaturi et al. 
found that the TR significantly worsened in the active pacing group indicating that the pacing 
settings were more influential than the actual presence of an RV lead90.  
Other considerable explanations pertain solely to the dynamics limited to the interaction between 
lead and valve directly. In 2017, Rydlewska et al. conducted a study in which the chest rays of 
patients who had undergone cardiac device implantation were examined. The objective of the 





correlated to TR severity. Rydlewska et al. found that the following radiological signs of 
“insufficient lead length (…) or excessive lead length” correlated with a worse TR91.  
A study conducted by Celiker et al. in Japan examined echocardiographies of patients who had 
undergone PM implantation with either one or two leads placed. A significant increase in TR 
Grading was only observed in patients with two RV leads suggesting that the number of leads 
influences TV function92.  
4. 4. Is Echocardiography suitable for assessing TR? 
Another important aspect of this study is whether transthoracic echocardiography is an efficient 
method of detecting or measuring lead induced TR. Even though 2D TTEs are a standard method 
of examining heart valves, there are authors that suggest otherwise. On the one hand, 2D TTE is 
a useful, safe and an easily ready method for examining mechanical complications between PM 
leads and the TV. However, 3D echocardiography or TEE allow a much more detailed 
observation of the lead route within the heart93. A great benefit of using real time 3D 
echocardiography pertaining to TR is being able to view all three leaflets moving at once during 
a cardiac cycle94. A publication by Wardell et al. emphasized that echocardiography alone was 
not sufficient, or rather it had not delivered secure evidence in their study as to whether the lead 
itself was the direct cause of TR84. The publication suggested that if patients develop a worse TR 
after implantation, and no other left heart cardiac pathologies explain the symptoms, a lead 
induced TR was likely but could not be identified immediately via echocardiography84. 
Muraru et al. also emphasized the limitations of 2D echocardiography and suggest the use of 3D 
to be superior95. The authors reasoned as following: not all three leaflets are routinely visualized, 
“the maximal dimensions and spatial configuration of the oval, saddle-shaped tricuspid annulus 
cannot be precisely and reproducibly quantified by a single linear measure, (…) and TV leaflet 
commissures, coaptation orifice, and/or valve area planimetry are generally impossible to assess 
by 2DE, either from transthoracic or transesophageal approach, because an en face view of the 
entire valve is required (…)” 95. Murarau et al. mainly criticized that 2D echocardiography 
enables less detailed imaging. 
In a nutshell, 3D echocardiography is preferable if available. In clinical practice however, 2D 
echocardiography is usually more accessible. 2D echocardiography can be used to examine TR 





4. 5. Baseline Differences 
The observed baseline data in table 6 shows that the PM group and the control group were 
similar. Therefore, statistical and interpretational comparisons were justifiable.  The control 
group, who did not have a cardiac device implanted, had significantly more coronary stents 
implanted and suffered more from arterial hypertension. It is disputable whether these 
characteristics were reasons for which patients in the control were not operated within the 
context of receiving a PM or whether these characteristics were the aftermath of not having a 
device.   
4. 6. Possible Reasons for decreased Cumulative Survival 
As shown in figure 3, the patients in the PM group had a lower estimated probability of 
cumulative survival. It is not distinguishable which reason was mainly responsible for this. The 
PM group had an unaffected LVEF, however Thackrey et al. examined HF in paced patients and 
found that left ventricular dysfunction was in fact common in patients with a PM, however actual 
HF was only diagnosed after implantation and more often in patients with a single chamber 
PM96. If PM leads do not seem to have an effect on LVEF, then the presence of a PM must have 
another effect in the right heart function correlating to HF, as suggested in this study.  
Also, the main indications for a PM are arrhythmias. Specific arrhythmias are life-shortening 
conditions at the outset and thus patients suffering from arrhythmia already have a possible 
lower life expectancy than patients without arrhythmia97. Patients who receive an ICD are 
generally at a higher risk of sudden cardiac death- this is why they receive an ICD in the first 
place37.  
Furthermore, patients who have received a cardiac device were operated and hence are at risk of 
general post-operative complications such as infections or embolisms, which can cause death.  
4. 8. Limitations 
There were several limitations in this study. First of all, data collection in a retrospective study is 
finite. If certain information about exams and patients was missing, it was not possible to attain it 
at a later date. This resulted in some exams having to be excluded from the study because of 





Further limitations relate to the study population. The number of patients was not very large but 
was comparable to prior studies. Patients were selected and the control group was not assigned 
randomly. Also, the patients’ main diagnoses as to why consecutive TTE examinations were 
performed in the first place or why patients in the PM had received a cardiac device were not 
regarded. This led to the comparison of patients who had different underlying illnesses, even 
though patients were matched based on mutual characteristics.   
Additionally, a limitation pertaining to the echocardiographies was the inter observer 
variability98. The TTE examiners were fully qualified and experienced, but subjectivity to a 
certain degree could not be eliminated. Also, the higher the grading, the easier it is or moreover 
the more likely it is to measure echocardiographic parameters accurately and reliably56. In this 
study the majority of patients had lower TR gradings. This made measuring specific values in the 
TTEs more difficult.  
Lastly, there are limitations referring to the statistics applied in this study. TR Grading was an 
ordinal scaled variable. This did not allow the calculation of an actual mean. Moreover, not all 
variables were truly normally distributed. These criteria meant that certain mathematical 
approaches were not legitimized and confined statistical assertions.  
4. 9. Conclusion and Outlook 
This study revealed that an RV lead does not have an actual, real impact on the TV function. 
Current literature seemed to be more in agreement on a lead having an effect, however the harder 
evidence found in this study rationally provides evidence for the opposite.  
If the implantation of a cardiac device did in fact induce worse TV function, this study shows 
that it would be more likely due to accompanying illnesses or due to the primary indication 
patients have for receiving a cardiac device in the first place. Contrarily in common literature 
physical lead interference with the TV leaflets was a widely accepted explanation.  It still 
remains unclear whether or to what extent other factors might impact TV function, such as the 
exact lead placement within the ventricle, which leaflet is mostly affected, or whether the 
number of leads per device are relevant.  
This study helps identify which clinical factors or echocardiographic values remain uninfluenced 





implantation. It must however be differentiated between a low LVEF and actual symptomatic 
HF.  
This study also provided stronger evidence, that patients with a cardiac device have a greater 
mortality. However, it remains unclear as to whether this effect was due to the devices 
themselves or on external factors and accompanying diseases.  
Taking into consideration that intracardial leads could be a cause of TR, new types of PM 
implantations are being discussed, such as extracardiac leads or even leadless PMs. It seems 
reasonable to implement such new methods.  A recent study conducted by Salaun et al. supports 
this proposition. They examined 23 patients with  leadless PMs and found that there was no 
significant change in right ventricular and tricuspid valve paremeters99. Another benefit of 
epicardial leads is that they can be placed as necessary independent of anatomical coronary or 
cardiac difficulties or obstructions100. Meanwhile, leadless PMs are being implanted more 
regularly and technology has improved greatly. Subcutaneous defibrillators  or injectable loop 
recorders, which function as  small subcutaneous ECGs, are further examples of technological 
developments towards the direction of extracardiac devices101.  
Additional research is needed in order to differentiate the increased mortality in patients with a 
cardiac device. The research questions of this study need to be investigated by further studies 
with a greater study population and more exact imaging techniques in order to discriminate 
between morphological and indirect parameters. If procedural changes regarding cardiac device 
implantation occur within the scope of the technological advancements, they could affect a large 
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